Bulletin
Investor Alert

New York Markets Close in:

press release

April 30, 2019, 8:01 a.m. EDT

CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

NEWARK, Apr 30, 2019 (GLOBE NEWSWIRE via COMTEX) -- NEWARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. /zigman2/quotes/201917619/composite CBAY +8.73% , a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2019 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13688866. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events .

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placEbo-coNtrolled, randomized, pHAse 3 study to evaluate the safety aNd effiCacy of sEladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for PBC. Seladelpar also received Breakthrough Therapy Designation from the FDA and PRIority MEdicine status from the EMA for PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.

For additional information about CymaBay visit www.cymabay.com .

Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

(C) Copyright 2019 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 4.80
+0.39 +8.73%
Volume: 485,030
Oct. 15, 2019 1:44p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$302.97 million
Rev. per Employee
N/A
loading...

Link to MarketWatch's Slice.